Presbyopia Market Report 2026

The presbyopia market size has grown strongly in recent years. It will grow from $10.66 billion in 2025 to $11.26 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to aging global population, increasing prevalence of age-related vision disorders, widespread availability of corrective eyewear, expansion of ophthalmology clinics, improvements in vision correction technologies.

The presbyopia market size is expected to see strong growth in the next few years. It will grow to $13.88 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to increasing adoption of premium vision correction solutions, rising demand for surgical presbyopia treatments, expansion of outpatient eye care services, growing investments in ophthalmic R&D, increasing awareness of vision health management. Major trends in the forecast period include increasing adoption of advanced lens implant technologies, rising demand for progressive and multifocal solutions, growing use of minimally invasive surgical treatments, expansion of personalized vision correction options, enhanced focus on visual comfort and quality.

The increasing prevalence of vision impairment is expected to drive the growth of the presbyopia market in the coming years. Vision impairment refers to a condition in which an individual experiences partial or complete loss of eyesight that cannot be fully corrected with glasses, contact lenses, or medical treatment. The rising occurrence of vision impairment is largely attributed to an aging population, a growing incidence of diabetes and eye-related diseases, increased screen exposure, and limited access to eye care services in certain regions. Presbyopia contributes to vision impairment by diminishing the eye’s ability to focus on nearby objects due to age-related stiffening of the lens, making routine activities such as reading and screen use more difficult without corrective solutions. For instance, in February 2025, according to the American Foundation for the Blind, a US-based non-profit organization, approximately 625,000 children in the United States were reported to have vision problems, based on data from the 2023 American Community Survey. Therefore, the rising prevalence of vision impairment is supporting the growth of the presbyopia market.

Major companies operating in the presbyopia market are emphasizing advanced innovations, including eye-responsive progressive lenses, to improve visual clarity and comfort for aging individuals. Eye-responsive progressive lenses are sophisticated multifocal lenses that adjust to eye movements, enabling smooth and continuous vision correction across all distances for individuals with presbyopia. For instance, in August 2023, Essilor, a France-based company engaged in the design, manufacture, and sale of ophthalmic lenses, introduced Varilux, a line of progressive lenses developed for people with presbyopia. This innovation integrates artificial intelligence to anticipate visual behavior using exclusive real-world data, establishing a new benchmark in personalized vision correction. Such advancements are reshaping the presbyopia market by offering enhanced solutions to manage age-related vision changes and improve overall quality of life.

In January 2023, Bausch + Lomb, a Canada-based eye health company specializing in ophthalmic pharmaceuticals, acquired AcuFocus for an undisclosed amount. Through this acquisition, Bausch + Lomb aims to strengthen its vision care portfolio by incorporating AcuFocus’ small-aperture technologies, including the IC-8 Apthera intraocular lens designed for patients with presbyopia and cataracts. AcuFocus is a US-based company focused on developing ophthalmic medical devices for the treatment of presbyopia and other vision-related disorders.

Major companies operating in the presbyopia market are Johnson & Johnson Private Limited, AbbVie Inc., Abbott Laboratories, Novartis AG, Essilor International SAS, Carl Zeiss Meditec AG, Alcon Vision LLC, Bausch + Lomb Corporation, CooperVision Inc., Santen Pharmaceutical Co. Ltd., Glaukos Corporation, STAAR Surgical Company, Ziemer Ophthalmic Systems AG, LENZ Therapeutics Inc., InSight Vision Incorporated, Oculis Holding AG, Orasis Pharmaceuticals Inc., Visus Therapeutics Inc., Eyenovia Inc., Atia Vision Inc.

North America was the largest region in the presbyopia market in 2025. The regions covered in the presbyopia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the presbyopia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the presbyopia market by increasing costs of imported ophthalmic devices, intraocular lenses, surgical equipment, and specialty eyewear materials. Hospitals and specialty eye clinics in North America and Europe are most affected due to reliance on imported optical technologies, while Asia-Pacific faces higher manufacturing and export costs for lenses and devices. These tariffs are raising treatment and product prices for patients. However, they are also encouraging domestic lens manufacturing, regional production of ophthalmic devices, and innovation in cost-efficient vision correction solutions.

The presbyopia market research report is one of a series of new reports that provides presbyopia market statistics, including presbyopia industry global market size, regional shares, competitors with a presbyopia market share, detailed presbyopia market segments, market trends and opportunities, and any further data you may need to thrive in the presbyopia industry. This presbyopia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Presbyopia is an age-related vision condition in which the eye’s lens gradually loses its ability to remain flexible, making it harder to focus on nearby objects. It usually begins around the age of 40 and progressively worsens over time. Common management options include reading glasses, bifocals, progressive lenses, and surgical procedures.

The primary treatment options for presbyopia include eyeglasses, contact lenses, refractive surgery, lens implants, and others. Eyeglasses are optical devices consisting of lenses mounted within a frame and are used to correct vision problems such as nearsightedness, farsightedness, astigmatism, and presbyopia. Presbyopia is associated with symptoms including eye strain, headaches, fatigue, blurred vision, and others, and treatments are utilized across various end users such as hospitals, specialty clinics, home care settings, and others.

The presbyopia market consists of revenues earned by entities by providing services such as corneal inlay procedures, refractive surgery services, and vision therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The presbyopia market includes sales of bifocal lense, multifocal contacts, refractive lens exchange (RLE), and prescription eye drops. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.